Dec 9 2011
Signal Genetics announced today, at the American Society of Hematology Annual Meeting, that the Company is launching its next generation Multiple Myeloma product, MyPRS Plus™, effective January 1, 2012. Signal Genetics is a privately held predictive genetic testing company focused on oncology. In addition to providing the benefits of the earlier product, which effectively stratifies Multiple Myeloma patients between those at high vs. low risk for relapse and overall survival, MyPRS Plus™ provides additional insights in to the genetic characteristics of each individual patient and identifies the molecular sub-group to which each patient belongs. This classification is the most granular predictor of relapse and survival available for Myeloma patients.
According to Dr. John Shaugnessy, EVP of Research for Myeloma Health LLC, a subsidiary of Signal Genetics, "Published data have shown that multiple myeloma is not a single homogeneous disease, and in the case of newly diagnosed myeloma, patients can be divided into seven distinct classes or subgroups. MyPRS Plus™ provides this classification, enabling physicians to better understand the genetic abnormalities of their patients and use this information to make informed decisions."
Joe Hernandez, President and CEO of Signal Genetics said, "The launch of our second generation Myeloma product is an indication of the strong adoption of our core product, our customers' request for even more information to help them determine the best therapeutic and treatment approach possible for their patients, and our continued commitment to patients with Multiple Myeloma."
New research highlights genetics as key factor in BMI and obesity risk